USANA Health Sciences (NYSE:USNA) Posts Quarterly Earnings Results, Beats Expectations By $0.07 EPS

USANA Health Sciences (NYSE:USNA) posted its quarterly earnings results on Tuesday. The company reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.49 by $0.07, Yahoo Finance reports. The business had revenue of $200.22 million during the quarter, compared to analysts’ expectations of $208.45 million. USANA Health Sciences had a net margin of 6.30% and a return on equity of 10.80%. During the same quarter in the prior year, the company posted $0.59 EPS. USANA Health Sciences updated its FY 2024 guidance to 2.450-2.450 EPS.

USANA Health Sciences Stock Performance

NYSE:USNA opened at $36.58 on Thursday. The stock has a market capitalization of $696.85 million, a P/E ratio of 12.93, a PEG ratio of 1.15 and a beta of 0.89. The company has a 50 day moving average price of $37.98 and a 200 day moving average price of $42.55. USANA Health Sciences has a fifty-two week low of $34.15 and a fifty-two week high of $55.45.

Analyst Upgrades and Downgrades

USNA has been the subject of a number of research analyst reports. DA Davidson lowered their price objective on shares of USANA Health Sciences from $38.00 to $35.00 and set a “neutral” rating for the company in a research report on Wednesday. StockNews.com cut shares of USANA Health Sciences from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 24th.

Insider Buying and Selling

In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In other USANA Health Sciences news, insider Paul A. Jones sold 6,266 shares of the stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $38.38, for a total transaction of $240,489.08. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director John Turman Fleming sold 1,000 shares of the stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $44.43, for a total transaction of $44,430.00. Following the sale, the director now owns 2,503 shares in the company, valued at approximately $111,208.29. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 7,940 shares of company stock valued at $311,670. Company insiders own 0.33% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.